GSK submitted Dabrafenib and Trametinib combination drug listing applications
Glaxo Shi Keji in a late-stage clinical trial data submitted by the United States and Trametinib Dabrafenib drug compound composed of a listing application, which the combination drug for the treatment of melanoma, its listing application submitted more than industry analysts expected to be earlier. The move highlights the growing number of pharmaceutical companies that highly specific cancer drugs through the relatively small-scale tests can confirm the value of their own, which they also accelerated the process of entering the market.
The FDA in May of this year were approved Dabrafenib and Trametinib listed. Tafinlar (Dabrafenib) belongs to a class of cancer drugs BRAF inhibitor, and Mekinist (Trametinib) can inhibit one with cancer-related protein (MEK). Both components of the compound drugs are drugs that can produce more effective against melanoma and lasting therapeutic effect, while the two drugs is also considered to be composed of two compound drugs major commercial opportunities.
GSK submitted Dabrafenib and Trametinib combination drug listing applications
ReplyDeleteGlaxo Shi Keji in a late-stage clinical trial data submitted by the United States and Trametinib Dabrafenib drug compound composed of a listing application, which the combination drug for the treatment of melanoma, its listing application submitted more than industry analysts expected to be earlier. The move highlights the growing number of pharmaceutical companies that highly specific cancer drugs through the relatively small-scale tests can confirm the value of their own, which they also accelerated the process of entering the market.
The FDA in May of this year were approved Dabrafenib and Trametinib listed. Tafinlar (Dabrafenib) belongs to a class of cancer drugs BRAF inhibitor, and Mekinist (Trametinib) can inhibit one with cancer-related protein (MEK). Both components of the compound drugs are drugs that can produce more effective against melanoma and lasting therapeutic effect, while the two drugs is also considered to be composed of two compound drugs major commercial opportunities.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Lurasidone Hydrochloride
Adoprazine
Rotigotine
Rotigotine hydrochloride
HOKU-81
Olmesartan
Olmesartan medoxomil
BML-190
AM630
Adoprazine